-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Intravenous thrombolysis (IVT) is the main method for the treatment of acute ischemic stroke (AIS)
.
In order to increase the proportion of AIS patients receiving intravenous thrombolytic therapy, a lot of efforts have been made and the time window for effective implementation of thrombolytic therapy has been expanded
Stroke vessels Recently, researchers have evaluated whether AIS IVT can cause UIA rupture and intracranial hemorrhage (ICH) in patients with unruptured UIA
Researchers conducted a prospective cohort study of consecutive patients treated at a comprehensive stroke center between 2005 and 2019
.
The radiology reports and records of the Finnish Medical Registry were evaluated to determine the patients with UIAs among all AIS patients undergoing IVT treatment at the center, and the aneurysm characteristics in the angiography of the patients after IVT were analyzed, as well as other brain imaging examinations.
- During the 15-year study period, a total of 3953 patients received IVT treatment
.
Among the 3953 AIS patients, 132 (3.
For patients with acute cerebral infarction with unruptured intracranial aneurysms, including larger UIA (≥10mm), intravenous thrombolysis appears to be safeLiterature source: https://n.
https://n.
neurology.
org/content/early/2021/10/06/WNL.
0000000000012771.
long leave a message here